Cefradine
Synonym(s):Cefradin;Cephradine;Cephradine dihydrate
- CAS NO.:38821-53-3
- Empirical Formula: C16H19N3O4S
- Molecular Weight: 349.4
- MDL number: MFCD00865048
- EINECS: 254-137-8
- SAFETY DATA SHEET (SDS)
- Update Date: 2024-11-07 13:31:19
What is Cefradine?
Description
Cefradine is an orally bioavailable β-lactam cephalosporin antibiotic. It is active against S. pyogenes, E. coli, K. pneumoniae, and E. cloacae (MICs = 0.04, 9.4, 9.4, and 6.3 μg/ml, respectively). Cefradine is also active against clinical isolates of S. aureus (MICs = 0.8-6 μg/ml) and S. pyogenes (MICs = 0.1-0.4 μg/ml), as well as H. influenzae, E. coli, and K. pneumoniae (MICs = 6.2-12.5 μg/ml). It increases survival in mouse models of systemic lethal infection by S. pyogenes, E. coli, K. pneumoniae, or E. cloacae (ED50s = 5, 37, 122, and 50 mg/kg, respectively), as well as by penicillin-susceptible or -resistant strains of S. aureus (ED50s = 18 and 91 mg/kg, respectively). Formulations containing cefradine have previously been used in the treatment of respiratory and urinary tract infections, skin infections, and otitis media.
Description
In cephradine, an interesting drug design device has been used. The aromatic ring in the ampicillin side chain has been partially hydrogenated by a Birch reduction such that the resulting molecule is still planar and π-electron excessive but has no conjugated olefinic linkages. It is comparatively acid stable and, therefore, is rapidly and nearly completely absorbed from the GI tract. Cephradine has the useful characteristic that it can be used both orally and IM so that parenteral therapy can be started in an institutional setting and then the patient can be sent home with the oral form, thus avoiding the risk of having to establish a different antibiotic. This is consistent with the present economics requiring sending patients home earlier than some physicians prefer. Unfortunately, however, for other reasons the IM and intravenous (IV) versions of cephradine are no longer available in the United States.
Description
This drug is very similar to cephalexin in its antimicrobial activity and in most other respects (Moellering and Swartz, 1976). Unlike cephalexin, for which a parenteral preparation is not generally available, cephradine is marketed in some countries (for example, Portugal) for both oral and parenteral use.
Chemical properties
Solid
Originator
Sefril,Squibb,Switz.
The Uses of Cefradine
Cephalosporin antibacterial.
The Uses of Cefradine
Cephradine is a first generation cephalosporin antibiotic. Cephradine has broad spectrum of bactericidal activity against infections caused by Streptococcus, Staphylococcus, Diplococcus pneumoniae, Es cherichia, Klebsiella, Salmonella, and indole-negative Proteus.
The Uses of Cefradine
A semi-synthetic cephalosporin antibiotic that is used to study the effect of expression, binding, and inhibition of PBP3 and other penicillin-binding proteins (PBPs) on bacterial cell wall mucopeptide synthesis
What are the applications of Application
Cephradine is a cephalosporin β-lactam antibiotic
Background
A semi-synthetic cephalosporin antibiotic.
Definition
ChEBI: A cephalosporin with a methyl substituent at position 3, and a (2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetamido substituent at position 7, of the cephem skeleton.
What are the applications of Application
Cephradine was synthesized by the Squibb Institute of Medical Research in 1971. It shows almost the same antibacterial activity and pharmacokinetic properties as cephalexin. Cephradine has been used for therapy of urinary and respiratory tract infections caused by Staphylococcus, Streptococcus, Escherichia coli, Klebsiella, and Proteus mirabilis.
Manufacturing Process
In a first step, D-2-amino-2-(1,4-cyclohexadienyl)acetic acid is obtained as
follows. A solution of 11.0 g (72.7 mmol) of D-phenylglycine in 900 ml
distilled ammonia (which has been treated with 45 mg lithium after distillation
to destroy traces of moisture) is slowly diluted with 370 ml dry ten-butyl
alcohol.
Over a period of hours, 1.65 g lithium (3.27 eq) is added in small portions
until a permanent blue color is obtained. The blue reaction mixture is then
treated with 38 g of triethylamine hydrochloride. The ammonia is allowed to
evaporate at room temperature overnight and the residual solvent is
evaporated at reduced pressure. The white residue is taken up in a small
amount of methanol-water and added to 4 liters of cold 1:1 chloroform-acetone to precipitate the crude product. After 20 minutes stirring the
suspension is filtered and the white filter cake dried in vacuo; the filter cake is
then pulverized and submitted once more to the precipitation process from
1:1 chloroform-acetone.
The white, crystalline product, 11.8 g, MP 297°C (dec), [α]D -89.7 (2 N NaOH)
is quantitatively obtained but is slightly contaminated with lithium chloride,
0.6% ionic chlorine being found by analysis.
The product of a second step is the methyl acetoacetic ester enamine of N-2-
amino-2-(1,4-cyclohexadienyl)acetic acid sodium salt. 306 mg D-2-amino-2-
(1,4-cyclohexadienyl)acetic acid (2.00 mmol) are dissolved by warming in a
solution of 108 mg of NaOCH3 (2.00 mmol) in 4.3 ml reagent grade MeOH.
255 mg (0.24 ml, 2.20 mmol) methyl acetoacetate are added and the mixture
refluxed for 45 minutes. The MeOH is almost totally stripped off in vacuo. Five
milliliters benzene are added and distilled off to a small residual volume. The
addition and distillation of benzene is repeated to insure complete removal of
the MeOH and water. The product crystallizes out overnight from a small
residual volume of benzene. It is filtered off, washed with benzene, and dried in vacuo. Yield 463 mg.
Then 3-deacetoxy-7-aminocephalosporanic acid is condensed with the above
described sodium salt in the presence of triethylamine to give cephradine.
brand name
Anspor (GlaxoSmith- Kline); Velosef (Bristol-Myers Squibb).
Therapeutic Function
Antibiotic
Antimicrobial activity
Cephradine. A semisynthetic cephalosporin available in both
oral and injectable forms. The antibacterial spectrum and
susceptibility to β-lactamases are almost identical to those of
cefalexin .
It is almost completely absorbed when given by mouth. A
500 mg oral dose achieves a concentration of about 18–20
mg/L after 1 h. The peak is delayed and reduced by food, but
the half-life is not altered. Intramuscular administration of
1 g results a plasma concentration of 10–12 mg/L within 2 h.
The plasma half-life is around 1 h and protein binding low.
Concentrations of up to 40% of those simultaneously
found in the serum have been demonstrated in lung tissue.
Penetration into the CSF is poor. Levels in sputum were
about 20% of those simultaneously present in the plasma following
a 1 g oral dose and similar levels have been found in
bone. Breast milk concentrations approaching 1 mg/L have
been found after 500 mg orally every 6 h and similar concentrations
have been found in amniotic fluid. Cord blood concentration
is said to be similar to that in the maternal blood.
It is excreted unchanged in the urine mostly in the first 6 h,
achieving concentrations exceeding 1 g/L. Probenecid markedly
increases the plasma concentration and delays the peak.
There is some biliary excretion.
The parenteral forms may give rise to local pain or thrombophlebitis.
Other side effects common to cephalosporins
have been described. In some patients Candida vaginitis has
been troublesome.
Clinical use is similar to that of cefalexin, but it has been
largely superseded by later cephalosporins.
Clinical Use
Cephradine (Anspor, Velosef) is the only cephalosporinderivative available in both oral and parenteral dosageforms. It closely resembles cephalexin chemically (it maybe regarded as a partially hydrogenated derivative ofcephalexin) and has very similar antibacterial and pharmacokineticproperties.
It occurs as a crystalline hydrate that is readily soluble inwater. Cephradine is stable to acid and absorbed almostcompletely after oral administration. It is minimally proteinbound and excreted almost exclusively through the kidneys.It is recommended for the treatment of uncomplicated urinarytract and upper respiratory tract infections caused bysusceptible organisms. Cephradine is available in both oraland parenteral dosage forms.
Synthesis
Cefradin, [6R-[6|á,7|?(R)]]-3-methyl-8-oxo-7-[(amino-1,4-cyclohexadien-1-
ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-en-2-carboxylic acid (32.1.2.13), is a close analog of cephalexin and differs in that the phenyl group in phenylglycine is partially hydrated to a 1,4-cyclohexadienyl moiety.
It is synthesized from phenylglycine, which is partially
reduced by lithium in liquid ammonia, which forms 1,4-cyclohexadienylglycine (32.1.2.11),
and the amino group in this compound is protected by reacting it with methyl acetoacetate in
the presence of sodium methoxide. The resulting salt (32.1.2.12) is transformed into a mixed
anhydride by a reaction with ethyl chloroformate in triethylamine, and reacted with deacetoxylated 7-aminocephalosporanic acid, which gives cefradin (32.1.2.13).
Drug interactions
Potentially hazardous interactions with other drugs
Anticoagulants: effects of coumarins may be
enhanced.
Metabolism
Not Available
Metabolism
Cefradine is excreted unchanged in the urine by glomerular filtration and tubular secretion, over 90% of an oral dose or 60-80% of an intramuscular dose being recovered within 6 hours. Probenecid delays excretion.
Properties of Cefradine
Melting point: | 140-142 C |
Boiling point: | 898℃ |
Density | 1.2794 (rough estimate) |
refractive index | 1.6320 (estimate) |
Flash point: | >110°(230°F) |
storage temp. | Keep in dark place,Inert atmosphere,2-8°C |
solubility | 1 M NH4OH: soluble50mg/mL |
form | powder |
pka | 2.63, 7.27(at 25℃) |
color | White |
Water Solubility | Soluble in water |
Stability: | Light Sensitive |
CAS DataBase Reference | 38821-53-3(CAS DataBase Reference) |
Safety information for Cefradine
Signal word | Danger |
Pictogram(s) |
Exclamation Mark Irritant GHS07 Health Hazard GHS08 |
GHS Hazard Statements |
H315:Skin corrosion/irritation H317:Sensitisation, Skin H319:Serious eye damage/eye irritation H334:Sensitisation, respiratory H335:Specific target organ toxicity, single exposure;Respiratory tract irritation |
Precautionary Statement Codes |
P280:Wear protective gloves/protective clothing/eye protection/face protection. P302+P352:IF ON SKIN: wash with plenty of soap and water. P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing. |
Computed Descriptors for Cefradine
New Products
ALUMINIUM IODIDE 100 GM BUFFER CAPSULE PH 7.0 - 10 CAP BUFFER SOLUTION PH 9.5 (BORATE) EZEE BLUE GEL STAINER BORAX CARMINE (GRENACHERS ALCOHOLIC) POTASSIUM IODATE - IODIDE SOLN 0.1 N Dabigatran Acyl-O3-D-Glucuronide Trifluoroacetic Acid Salt Isofolic Acid Dabigatran 2-O-acylglucuronide metabolite Dabigatran Acyl-?-D- glucuronide Trifluroacetic Acid Erythromycin EP Impurity A Desloratidine Related Compound ARelated products of tetrahydrofuran
You may like
-
38821-53-3 Cefradine 98%View Details
38821-53-3 -
Cefradine CAS 38821-53-3View Details
38821-53-3 -
Cephradine CAS 38821-53-3View Details
38821-53-3 -
Cephradine CAS 38821-53-3View Details
38821-53-3 -
Dechloro DesloratadineView Details
-
Edoxaban Impurity 57View Details
2089454-69-1 -
Empagliflozin Bromo ImpurityView Details
-
Ipratropium EP Impurity BView Details
58073-59-9